<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393703</url>
  </required_header>
  <id_info>
    <org_study_id>15-015</org_study_id>
    <nct_id>NCT02393703</nct_id>
  </id_info>
  <brief_title>Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer</brief_title>
  <official_title>Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of&#xD;
      important proteins and nucleic acids that serve as messenger systems in the blood and tissue.&#xD;
      Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue&#xD;
      from patients with noncancerous pancreatic disease. Including patients without cancer will&#xD;
      allow the investigators to establish &quot;normal&quot; values, which currently do not exist. The&#xD;
      investigators will then look to see whether exosome activity has a connection to disease&#xD;
      recurrence and outcomes in patients. The results of this study will be the basis for future&#xD;
      studies exploring this area.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>successful isolation of exosomes</measure>
    <time_frame>1 year</time_frame>
    <description>isolation of at least 100,000 microvesicles is needed for exosomes purification for down stream applications such as proteomics and RNA sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the liver microenvironment</measure>
    <time_frame>1 year</time_frame>
    <description>for alterations in cellular infiltrate and ECM using IF and IHC</description>
  </secondary_outcome>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Benign Pancreatic Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, pancreatic fluid, and pancreas tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSKCC clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients â‰¥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete&#xD;
             pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma,&#xD;
             intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors,&#xD;
             without an invasive component; or other benign pancreatic disease will be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of metastatic disease or disease that precludes resection&#xD;
&#xD;
          -  Receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months&#xD;
             of being enrolled in the study&#xD;
&#xD;
          -  INR &gt;2&#xD;
&#xD;
          -  Known clotting factor deficiency or hypercoagulable state&#xD;
&#xD;
          -  Any patient with the need or anticipated need for full anti-coagulation during&#xD;
             hospitalization for the resection.&#xD;
&#xD;
          -  Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to&#xD;
             resection.&#xD;
&#xD;
          -  IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion&#xD;
             for invasive component Additionally, if at the discretion of the operating surgeon,&#xD;
             blood collection would lead to undue morbidity, the patient will be excluded and&#xD;
             replaced&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Jarnagin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Jarnagin, MD</last_name>
    <phone>212-639-7601</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Kingham, MD</last_name>
    <phone>212-639-5260</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William R Jarnagin, MD</last_name>
      <phone>212-639-7601</phone>
    </contact>
    <contact_backup>
      <last_name>Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact_backup>
    <investigator>
      <last_name>William R Jarnagin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exosomes</keyword>
  <keyword>15-015</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

